AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: therapy

US WorldMeds Receives the Sarcoma Foundation of America’s 2026 Vision of Hope Award

Company recognized for advancing treatment options in sarcoma and for embedding the patient advocacy perspective into its development and regulatory workLOUISVILLE, Ky., Oct. 9,...

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

ARC Stages Singapore’s First Full-Sized Humanoid Fight Night

Professional Martial Artists Pilot Robots REAL-TIME on StageSINGAPORE, Oct. 9, 2026 /PRNewswire/ -- ARC held Singapore's first full-sized humanoid fight night at *SCAPE on...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid...

Inglewood Bids to Become America’s Second Blue Zone City, Powered by InBody

CERRITOS, Calif., Oct. 8, 2026 /PRNewswire/ -- InBody today announced the launch of a one-year fall prevention pilot with the City of Inglewood and...

Global Dog Harness Market to Grow at 6.8% CAGR as Pet Humanization, Safety Awareness and Premium Ergonomic Harness Demand Accelerate, reports Maximize Market Research

PUNE, India, Oct. 7, 2026 /PRNewswire/ -- The Global Dog Harness Market is witnessing steady growth, rising from USD 1.62 Billion in 2025 to an...

Global Dog Harness Market to Grow at 6.8% CAGR as Pet Humanization, Safety Awareness and Premium Ergonomic Harness Demand Accelerate, reports Maximize Market Research

PUNE, India, Oct. 7, 2026 /PRNewswire/ -- The Global Dog Harness Market is witnessing steady growth, rising from USD 1.62 Billion in 2025 to an...

Boehringer Ingelheim’s New Quarterable Snap-Tab PREVICOX® (firocoxib) Chewable Tablets Provide Flexible Dosing for Dogs in the U.S.

Now approved by the U.S. Food and Drug Administration, this unique tablet design enables more precise, customizable dosing based on dog's weight, as well...

/C O R R E C T I O N — Privo Technologies/

In the news release, Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer,...

Resolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren’s Disease

Approximately 110 participants enrolled in randomized, double-blind, placebo-controlled study; topline results expected in the second quarter of 2027MIAMI, Oct. 7, 2026 /PRNewswire/ -- Resolve...

MintNeuro raises $5 million to scale purpose-built chip platform for neural devices and brain-computer interfaces

Funding from European and US investors will accelerate product launch, partner adoption and international expansionLONDON, Oct. 7, 2026 /PRNewswire/ -- MintNeuro, a semiconductor company...

MintNeuro raises $5 million to scale purpose-built chip platform for neural devices and brain-computer interfaces

Funding from European and US investors will accelerate product launch, partner adoption and international expansionLONDON, Oct. 7, 2026 /PRNewswire/ -- MintNeuro, a semiconductor company...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy